TERT promoter mutations and long-term survival in patients with thyroid cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Tae Hyuk | - |
dc.contributor.author | Kim, Young Eun | - |
dc.contributor.author | Ahn, Soomin | - |
dc.contributor.author | Kim, Ji-Youn | - |
dc.contributor.author | Ki, Chang-Seok | - |
dc.contributor.author | Oh, Young Lyun | - |
dc.contributor.author | Kim, Kyunga | - |
dc.contributor.author | Yun, Jae Won | - |
dc.contributor.author | Park, Woong-Yang | - |
dc.contributor.author | Choe, Jun-Ho | - |
dc.contributor.author | Kim, Jung-Han | - |
dc.contributor.author | Kim, Jee Soo | - |
dc.contributor.author | Kim, Sun Wook | - |
dc.contributor.author | Chung, Jae Hoon | - |
dc.date.accessioned | 2022-07-15T19:28:05Z | - |
dc.date.available | 2022-07-15T19:28:05Z | - |
dc.date.created | 2021-05-14 | - |
dc.date.issued | 2016 | - |
dc.identifier.issn | 1351-0088 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/155389 | - |
dc.description.abstract | TERT promoter mutations are emerging prognostic biomarkers in multiple cancers and are found in highly aggressive thyroid cancer. Our aim is to investigate the prognostic value of these mutations for the outcome of thyroid cancer-related mortality in a large cohort of thyroid cancer patients. This was a retrospective study of 409 patients (393 with differentiated thyroid cancer) with a median age of 44 years (range 16–81 years) and median follow-up of 13 years (interquartile range 11–16 years). Analyses of associations between mutational status and various clinicopathological variables were performed. TERT promoter mutations were identified in 32 (9.8%) papillary, 11 (16.7%) follicular and seven (43.8%) poorly differentiated/anaplastic thyroid cancer patients. The presence of TERT promoter mutations was associated with factors such as increased age (P < 0.001), extrathyroidal invasion (P = 0.01), increased stage at diagnosis (P < 0.001) and dedifferentiated histological type (P = 0.001). A TERT promoter mutation was independently associated with poorer overall survival in patients with differentiated thyroid cancer (10-year survival rate, 66.2% vs 98.3% for wild type; adjusted HR, 7.18; 95% CI: 2.77–18.59) and in patients with papillary cancer (74.2% vs 99.3%; 14.20; 3.03–66.68). Concomitant TERT and BRAF mutations worsened the survival rate of patients with papillary cancer (82.6% vs 99.4% for exclusively BRAF mutation alone; 5.62; 1.85–17.09). In conclusion, the presence of TERT promoter mutations is independently associated with increased mortality in patients with differentiated thyroid cancer. The results suggest that inclusion of TERT promoter mutation analysis with conventional clinicopathological evaluation can lead to better prognostication and management for individual patients. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | BIOSCIENTIFICA LTD | - |
dc.title | TERT promoter mutations and long-term survival in patients with thyroid cancer | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Young Eun | - |
dc.identifier.doi | 10.1530/ERC-16-0219 | - |
dc.identifier.scopusid | 2-s2.0-84994036107 | - |
dc.identifier.wosid | 000387602700015 | - |
dc.identifier.bibliographicCitation | ENDOCRINE-RELATED CANCER, v.23, no.10, pp.813 - 823 | - |
dc.relation.isPartOf | ENDOCRINE-RELATED CANCER | - |
dc.citation.title | ENDOCRINE-RELATED CANCER | - |
dc.citation.volume | 23 | - |
dc.citation.number | 10 | - |
dc.citation.startPage | 813 | - |
dc.citation.endPage | 823 | - |
dc.type.rims | ART | - |
dc.type.docType | 정기학술지(Article(Perspective Article포함)) | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Endocrinology & Metabolism | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Endocrinology & Metabolism | - |
dc.subject.keywordPlus | BRAF V600E MUTATION | - |
dc.subject.keywordPlus | RAS MUTATIONS | - |
dc.subject.keywordPlus | PAPILLARY | - |
dc.subject.keywordPlus | ASSOCIATION | - |
dc.subject.keywordPlus | TELOMERASE | - |
dc.subject.keywordPlus | CELLS | - |
dc.subject.keywordPlus | FUSION | - |
dc.subject.keywordPlus | TUMORS | - |
dc.subject.keywordAuthor | BRAF | - |
dc.subject.keywordAuthor | Mortality | - |
dc.subject.keywordAuthor | Prognosis | - |
dc.subject.keywordAuthor | TERT promoter | - |
dc.subject.keywordAuthor | Thyroid cancer | - |
dc.identifier.url | https://erc.bioscientifica.com/view/journals/erc/23/10/813.xml | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.